New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
11:04 EDTTSM, XPO, ASH, OII, PPHMHigh option volume stocks: PPHM ASH TSM OII XPO
News For PPHM;ASH;TSM;OII;XPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:51 EDTPPHMPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
08:11 EDTASHAshland enters in to about $270M share repurchase agreements
Ashland announced that it has entered into uncollared accelerated share repurchase, or ASR, agreements with each of Deutsche Bank and JPMorgan Chase Bank, to repurchase an aggregate of approximately $270M of Ashland's common stock. These agreements are part of Ashland's previously announced $1.35B share repurchase program. Under the ASR agreements, Ashland has agreed to repurchase an aggregate of approximately $270M of its common stock from Deutsche Bank and JPMorgan, with immediate delivery of an aggregate of approximately 1.9M shares expected.
January 26, 2015
18:28 EDTASHOn The Fly: After Hours Movers
Subscribe for More Information
17:08 EDTASHAshland reports preliminary Q1 revenue down 3% y/y, consensus $1.44B
Subscribe for More Information
17:03 EDTASHAshland reports preliminary Q1 adjusted EPS $1.46, consensus $1.41
Reports preliminary Q1 adjusted EBITDA up 11% to $262M.
15:30 EDTASHNotable companies reporting after market close
Subscribe for More Information
January 25, 2015
13:57 EDTPPHMUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
10:07 EDTTSMHigh option volume stocks
High option volume stocks: CE TSM RYAM NOC SNE FXCM LBTYA TKMR LF STT
January 20, 2015
17:04 EDTOIIOceaneering announces Hess Stampede Project umbilicals and hardware contract
Subscribe for More Information
January 16, 2015
09:31 EDTPPHMPeregrine announces Ohase II clinical data of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In this single-center, single-arm, open-label investigator-sponsored trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression of 6.7 months, a disease specific survival of 8.7 months, a disease control rate of 58% and a 4-month progression-free survival of 62%. Two patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors. The secondary endpoint of median overall survival was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.
06:05 EDTTSMTSMC expects to lead FinFET segment in 2016 and beyond, DigiTimes says
TSMC Chairman Morris Chang said the company will gain a majority share in the FinFET segment in 2016 although it will lose to Samsung in 2015, reports DigiTimes. At its investors conference, Chang said TSMC will continue to lead the segment in 2017, 2018 and beyond. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use